# Perrigo Company plc (PRGO) — Investment Thesis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Tier:** Free primer (steps 1 & 3 of 19)  
**Sibling pages:** /stocks/PRGO/financials · /stocks/PRGO/memo

> This page shows the free thesis context (business model + recent catalysts).
> The full investment thesis (moat analysis, DCF, scenarios, risk register) is available
> via GET /api/v1/research/PRGO/memo ($2.00, Bearer token).

## Business Model

---
source: coverage-next-full
ticker: PRGO
step: "01"
title: Business Overview — Perrigo Company plc
created: 2026-05-29
---

### Step 01 — Business Overview

#### Company at a Glance

Perrigo Company plc is the **world's largest manufacturer of over-the-counter (OTC) store-brand (private-label) consumer healthcare products**. Headquartered in Dublin, Ireland, and listed on the NYSE, Perrigo operates as the hidden engine behind the store-brand OTC medicine shelves at Walmart, CVS, Walgreens, Target, Costco, Kroger, and Amazon. When a consumer reaches for the CVS-brand ibuprofen instead of Advil, there is a high probability it was manufactured by Perrigo.

The company pivoted decisively in 2021 by divesting its Rx pharmaceutical generics business to become a pure-play **consumer self-care** company. The subsequent acquisition of HRA Pharma in 2022 added a branded international OTC portfolio — shifting the mix toward branded products in Europe while maintaining the dominant private-label position in the Americas.

#### What Perrigo Does

Perrigo's core value proposition is straightforward: it develops, manufactures, and distributes store-brand equivalents of branded OTC products at materially lower prices, giving retailers high-margin, lower-cost alternatives to national brands. This "value brand" model benefits retailers (higher private-label margins vs. branded resale) and consumers (20–30% savings on therapeutically equivalent products).

Secondary value: In international markets (primarily Europe), Perrigo owns branded OTC products — not private-label — that compete directly with Haleon, Kenvue, and Reckitt product lines.

#### Business Segments

##### Consumer Self-Care Americas (CSCA) — ~55–67% of Revenue
The flagship segment. CSCA is the largest private-label OTC manufacturer in the United States. It manufactures and distributes store-brand equivalents across categories:

| Category | Example Products | National Brand Equiv. |
|----------|-----------------|----------------------|
| Analgesics | Store-brand ibuprofen, acetaminophen | Advil, Tylenol |
| Cough / Cold / Allergy | Store-brand DXM, guaifenesin, loratadine | NyQuil, Mucinex, Claritin |
| Gastrointestinal | Store-brand antacids, laxatives, anti-diarrheal | Tums, Dulcolax, Imodium |
| Smoking Cessation | Store-brand nicotine patches, gum | Nicorette, NicoDerm |
| Infant Nutrition | Store-brand infant formula | Similac, Enfamil (Abbott, Reckitt) |
| Women's Health | Opill® (OTC oral contraceptive) | First-mover in new OTC category |
| Eye / Ear Care | Store-brand eye drops, ear wax kits | Visine, Debrox |

**Opill®** (norgestrel 0.075mg) is noteworthy: the first-ever FDA-approved daily oral contraceptive available OTC without a prescription. Approved July 2023, launched early 2024. Perrigo holds the exclusive OTC right, representing a rare branded growth vector within CSCA.

**Infant Formula** (~$360M revenue, ~8–9% of total): Perrigo is the largest US private-label infant formula manufacturer (a market segment not supplied by Abbott or Mead Johnson). The 2022 Abbott recall created a temporary windfall. A strategic review was announced in November 2025 to evaluate divestiture or other options.

##### Consumer Self-Care International (CSCI) — ~33–45% of Revenue
A branded OTC portfolio in Europe and Australia, significantly enlarged by the HRA Pharma acquisition. Key brands:

| Brand | Category | Primary Markets |
|-------|----------|----------------|
| Compeed® | Blister/wound care | Europe-wide |
| Solpadeine® | Analgesic (codeine-containing) | UK, Ireland |
| Coldrex® | Cold/flu remedy | Central/Eastern Europe |
| Mederma® | Scar treatment | Europe |
| ellaOne® | Emergency contraceptive (HRA) | Europe |
| Plan B® | Emergency contraceptive (HRA, US) | US/Americas |
| Dermacosmetics | Skincare | Europe (under divestiture review) |

HRA Pharma also brought a pipeline of Rx-to-OTC switch projects — a strategic growth avenue for branded consumer health across Europe.

#### Transformation Story (2021–2026)

Perrigo's recent history is defined by two decisions of opposing nature:

**Rx Divestiture (2021):** Sold the prescription generics business, refocusing on consumer OTC. This simplified the business and reduced generic pharma pricing/volume risk. It also generated cash, temporarily improving the balance sheet.

**HRA Pharma Acquisition (2022):** Paid ~€1.8B for HRA Pharma, funded predominantly with debt. This added branded European OTC and reproductive health products (ellaOne, Plan B) but substantially levered the balance sheet (net leverage jumped to ~5x). Post-acquisition integration has been the dominant strategic focus since.

The net result: Perrigo is now a mid-complexity consumer health company with a leading private-label US franchise, a branded European portfolio, and a leveraged balance sheet in need of repair.

#### Key Facts

| Metric | Value (May 2026) |
|--------|----------------|
| Market Cap | ~$1.58B |
| Annual Revenue | ~$4.25B (FY2025) |
| Employees | ~9,000–10,000 |
| Listed | NYSE (PRGO); Euronext Dublin |
| Incorporated | Ireland |
| Fiscal Year | Calendar year (Dec 31) |
| Dividend | $1.16/share (~10% yield) |
| Net Leverage | ~4.5x adj. EBITDA (FY2025 est.) |

## Recent Catalysts

---
source: coverage-next-full
ticker: PRGO
step: "12"
title: Catalysts — Near-Term Drivers & Bull/Bear Cases
created: 2026-05-29
---

### Step 12 — Catalysts

#### Catalyst Timeline (2026–2027)

| Catalyst | Expected Timing | Bull Impact | Bear Impact |
|---------|----------------|-------------|-------------|
| Dermacosmetics sale closure | H1 2026 | ~$350M debt paydown → leverage ~4.2x | Lower than expected proceeds → less deleveraging |
| Infant formula strategic review conclusion | Q2–Q3 2026 | Sale at 1.2x rev → ~$430M proceeds | Buyer not found; retained at declining revenue |
| Project Energize savings delivery | FY2026 (full year) | $80–100M net savings flow → adj. EPS upside | Savings delayed; cost inflation offsets |
| Opill ramp Q2/Q3 2026 | Quarterly | Revenue inflection visible; new OTC category | Low consumer awareness; slow adoption |
| Q2 2026 earnings + leverage update | Aug 2026 | Adj. EBITDA expansion + leverage ratio moving toward 3x | Revenue miss + margin miss + guidance cut |
| FY2026 guidance raise | Q2–Q3 2026 | Market re-rates from deep value to recovery story | Guidance cut triggers credit/dividend concerns |
| Credit facility health (covenant compliance) | Ongoing | Continued compliance; no issues | Covenant stress triggers lender restrictions |
| Dividend review (cut/maintain) | Board decision | Maintain signals confidence (near-term positive) | Cut signals cash flow stress (short-term negative, long-term positive) |
| New Rx-to-OTC switch approval (EU pipeline) | 2027–2028 | High-multiple branded OTC category created | Regulatory rejection; R&D capital stranded |

#### Near-Term Catalysts (12 Months)

##### 1. Dermacosmetics Divestiture Completion (~$350M)
**Status:** Proposed sale announced July 2025; expected close H1 2026 (subject to regulatory approval)
**Impact:** Proceeds designated for debt reduction
- Best case: €327M (~$350M) received; net debt falls from ~$3.1B to ~$2.75B; leverage ratio improves ~0.4–0.5x
- This is the largest near-term debt reduction catalyst and has the highest probability of occurring (management-controlled)

##### 2. Infant Formula Strategic Review Outcome
**Status:** Announced November 2025; review ongoing; conclusion expected mid-2026
**Impact:** ~$360M revenue (~8–9% of total) at below-average margins
- Best case: Sale at 1.0–1.5x revenue (~$360–540M) significantly reduces leverage
- Base case: Sale at ~0.8–1.0x revenue; modest proceeds but removes a low-quality revenue stream
- Bear case: No qualified buyer; business retained; drag continues; strategic review overhang lingers

##### 3. Project Energize Savings Realization
**Target:** $140–170M gross annualized savings by end of FY2026 ($80–130M net)
**Impact:** First full-year benefit appears in FY2026 adj. EBITDA
- If ~$100M net savings flow through in FY2026: adj. EBITDA could reach $530–540M vs. ~$440M in FY2024
- This improvement would flow directly into FCF and reduce leverage ratio by ~0.3–0.4x organically
- **Highest-probability positive catalyst** — management has been specific and credible about this program

##### 4. Opill Revenue Ramp
**Status:** Launched OTC in early 2024; building distribution and awareness through 2025–2026
**Impact:** Modest near-term but meaningful optionality
- FY2026 Opill revenue estimate: $50–100M+ (immature; limited analyst consensus)
- Long-term: If oral contraceptive OTC market reaches $500M+ revenue category, Opill could become $200–400M business with strong margins
- Visibility-creating events: quarterly disclosure of new product revenue, distribution milestones

##### 5. Q2/Q3 2026 Earnings Inflection
Following Dermacosmetics divestiture close + Project Energize savings + Opill ramp:
- First quarter showing YoY adj. EBITDA margin expansion would be a sentiment catalyst
- Market re-pricing from "distressed value" to "restructuring success" could compress discount multiple
- Key metric: Does adj. EPS guidance midpoint rise above $2.40 (current consensus high-end)?

#### Negative Catalysts to Monitor

1. **Dividend cut announcement:** A dividend cut, while ultimately credit-positive, would be a stock price negative short-term and signal FCF stress
2. **Covenant breach or refinancing complications:** Any signal of lender stress would be severely negative
3. **FDA Warning Letter at major facility:** Immediate operational and financial impact; share price collapse risk
4. **Infant formula review fails to find buyer:** Retained drag + capital tied up in low-return asset
5. **CSCA pricing further compressed by retailer consolidation:** Margin miss triggers leverage concern spiral

---

**Bull Case**
- Project Energize delivers $100–130M net savings by end-FY2026, Dermacosmetics proceeds ~$350M reduce leverage to ~4x, and Opill emerges as a $150M+ revenue category-creating product; the combined effect drives adj. EBITDA from ~$440M toward $580–600M by FY2027, leverage hits <3x ahead of schedule, and the market re-rates from 8x to 12x adj. EBITDA, implying equity value of $15–22/share.
- Infant formula sale at ~1.2x revenue (~$430M) provides a second major debt paydown catalyst in H2 2026, accelerating the deleveraging timeline and potentially funding a dividend cut-to-reinvest or a credit upgrade.
- Consumer trade-down tailwind from persistent inflation drives CSCA private-label market share gains, inflecting organic revenue from -3% to +2%, while the 10% dividend yield attracts income investors and provides a valuation floor.

**Bear Case**
- Project Energize savings are offset by ongoing CSCA pricing concessions and input cost re-inflation, leaving adj. EBITDA stuck at $400–420M and leverage structurally above 4x; lenders add covenant restrictions that limit operational flexibility.
- The infant formula strategic review fails to find a buyer at acceptable terms, and the Dermacosmetics sale closes at a significant discount to the €327M ask, delivering <$200M in net proceeds; the combination leaves leverage elevated and raises dividend sustainability questions that management eventually cannot avoid.
- Opill faces unexpectedly slow consumer adoption (awareness, access, cost barriers) and becomes a rounding-error revenue contributor, while a new competitor pursues FDA approval for an OTC contraceptive, eliminating Perrigo's first-mover premium; PRGO stock tests new 52-week lows below $9 on leverage + growth fears.

## Full Investment Thesis (Premium)

The full research tier adds these thesis-critical dimensions:

- Moat Analysis — durable competitive advantages, switching costs, network effects
- Investment Thesis — variant perception, what has to be true, why market may be wrong
- Bull / Base / Bear Scenarios — probability weights, catalysts, price targets
- Risk Register — macro, competitive, execution, regulatory risks with materiality ratings
- Management Quality — capital allocation track record, incentive alignment
- DCF Valuation — 10-year model with sensitivity matrix

**API endpoint:** GET /api/v1/research/PRGO/memo

## Navigation

- Overview: /stocks/PRGO
- Financials: /stocks/PRGO/financials
- Thesis (this page): /stocks/PRGO/thesis
- Investment Memo: /stocks/PRGO/memo
- Coverage universe: /stocks